FDA Approves Baxdrostat for Resistant Hypertension - Top-Institutions - MDSpire

FDA Approves Baxdrostat for Resistant Hypertension

Phase 3 findings support the oral therapy in adults with persistent blood pressure elevation despite multidrug treatment.

  • By

  • Kathryn Wighton

  • May 18, 2026

  • 2 min

Share

Top Institutions in Cardiology

Brief introduction explaining scope and methodology.

  • #1

    University College London
    University College London

    London, England

    Key Differentiators

    • Cardiology

  • #2

    Sierra Eye Associates
    Sierra Eye Associates

    Sierra Vista, Arizona

    Key Differentiators

    • Ophthalmology

  • #3

    Columbia University College of Physicians and Surgeons
    Columbia University College of Physicians and Surgeons

    New York, New York

    Key Differentiators

    • Medicine

  • #4

    Mayo Clinic
    Mayo Clinic

    Rochester, Minnesota

    Key Differentiators

    • Medicine

Original Source(s)

FDA Approves Baxdrostat for Resistant Hypertension

  • by Kathryn Wighton

  • May 18, 2026

Related Content

Treatment of mild subclinical hypothyroidism and its impact on lipid metabolism

The effect of health literacy on quality of life in patients with heart failure: the mediating role of self-care confidence

The characteristics and clinical outcomes of atrial fibrillation patient in middle income country of Indonesia